Clinical Trial Details

USOR 16065

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Non-Hodgkins Lymphoma
Study Type: Interventional
Phase: III
Study Start Date: 02/10/2017
Study Completion Date: 07/2022

This is a randomized study to assess the efficacy and safety of the study drug ublituximab and TGR-1202 with or without Bendamustine and then TGR-1202 alone in patients with previously treated Non-Hodgkin’s Lymphoma.

NCT Number

NCT02793583

Principal Investigator(s)

Mohit Narang, MD

Sponsor(s)

TG Therapeutics, Inc.

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female